Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Neurocrine (NBIX – Research Report) and Climb Bio (CLYM – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Neurocrine (NBIX)
William Blair analyst Myles Minter maintained a Buy rating on Neurocrine today. The company’s shares closed last Thursday at $135.74.
According to TipRanks.com, Minter is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Neurocrine with a $180.60 average price target, implying a 29.4% upside from current levels. In a report released today, Truist Financial also maintained a Buy rating on the stock with a $169.00 price target.
See the top stocks recommended by analysts >>
Climb Bio (CLYM)
William Blair analyst Matt Phipps reiterated a Buy rating on Climb Bio today. The company’s shares closed last Thursday at $4.43.
According to TipRanks.com, Phipps is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Climb Bio with a $10.50 average price target.
